1.85  0.02 (1.09%)		08-04 09:30
Open: 1.85 High: 1.85 Volume: 12,568		Pre. Close: 1.83 Low: 1.84 Market Cap: 59(M)

Short term
Mid term
Targets	6-month :	18.14	1-year :	28.13
Resists	First :	15.53	Second :	24.09
Pivot price	2.55
Supports	First :	1.7	Second :	1.41
MAs	MA(5) :	2.43	MA(20) :	5.78
	MA(100) :	10.28	MA(250) :	10.41
MACD	MACD :	-2.4	Signal :	-2.3
%K %D	K(14,3) :	9.4	D(3) :	6.6
RSI	RSI(14): 36.1
52-week	High :	24.09	Low :	1.7

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ VACH ] has closed above bottom band by 36.3%. Bollinger Bands are 48.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	2.5 - 2.52	2.52 - 2.53
Low:	2.1 - 2.12	2.12 - 2.13
Close:	2.14 - 2.16	2.16 - 2.18

Voyager Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company intends to target the healthcare and healthcare-related industries.

Tue, 14 Jul 2026
Voyager Acquisition Corp (VACH) Holds Steady at $17.11 as SPAC Awaits Catalyst - KAMA Signal - dars.gov.et

Thu, 11 Jun 2026
VERAXA Biotech (NASDAQ: VRXA) Completes Business Combination, Begins Trading on Nasdaq - USA Today

Wed, 10 Jun 2026
VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026 - NTB Kommunikasjon

Thu, 28 May 2026
VERAXA Biotech Secures $27.5M Financing, to Go Public Via SPAC - finance.yahoo.com

Wed, 11 Mar 2026
Voyager Acquisition Corporation Announces Redemption Results in Connection with its Business Combination with VERAXA Biotech AG - finance.yahoo.com

Tue, 20 May 2025
VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer - BioSpace

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Financial Services
Industry: Shell Companies
Shares Out	25 (M)
Shares Float	0 (M)
Held by Insiders	1 (%)
Held by Institutions	10.4 (%)
Shares Short	1 (K)
Shares Short P.Month	2 (K)

EPS	0.2
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.42
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-0.9 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	-91.1 %
Operating Cash Flow	2 (M)
Levered Free Cash Flow	272 (M)

PE Ratio	10.28
PEG Ratio	0
Price to Book value	-5.15
Price to Sales	0
Price to Cash Flow	34.8

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.